Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$37.25 USD

37.25
683,172

-0.31 (-0.83%)

Updated Aug 4, 2025 11:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Gilead (GILD) Application for HIV Drug Validated in EU

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

    Zacks Equity Research

    Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

    by Zacks Equity Research

    Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

      Zacks Equity Research

      Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

      by Zacks Equity Research

      Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

        Zacks Equity Research

        Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion

        by Zacks Equity Research

        Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.

          Zacks Equity Research

          Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe

          by Zacks Equity Research

          Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.

            Zacks Equity Research

            Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

            by Zacks Equity Research

            Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

              Zacks Equity Research

              Glaxo's (GSK) Shingles Candidate Phase III Data Positive

              by Zacks Equity Research

              GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

                Zacks Equity Research

                Novartis Announces Positive Results for Cardiovascular Drug

                by Zacks Equity Research

                Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.

                  Zacks Equity Research

                  Novartis (NVS) Biosimilar of MabThera Approved in the EU

                  by Zacks Equity Research

                  Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon.

                    Zacks Equity Research

                    GlaxoSmithKline's Benlysta Positive in Continuation Trial

                    by Zacks Equity Research

                    GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).

                      Zacks Equity Research

                      Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?

                      by Zacks Equity Research

                      Let's put GlaxoSmithKline PLC (GSK) stock into this equation and find out if it is a good choice for value-oriented investors right now.

                        Zacks Equity Research

                        Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval

                        by Zacks Equity Research

                        Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.

                          Zacks Equity Research

                          Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen

                          by Zacks Equity Research

                          Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.

                            Zacks Equity Research

                            Novartis Presents Positive Data on CAR-T Cell Therapy Drug

                            by Zacks Equity Research

                            Novartis AG (NVS) announced data from an interim analysis from a phase II study on lymphoma candidate.

                              Zacks Equity Research

                              Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises

                              by Zacks Equity Research

                              Inovio Pharmaceuticals, Inc (INO) initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human papillomavirus.

                                Zacks Equity Research

                                Novartis' (NVS) Tasigna Receives Label Update Nod in EU

                                by Zacks Equity Research

                                Novartis AG (NVS) announced that the EC has approved the inclusion of Treatment-free Remission (TFR) data in the oncology drug Tasigna's label.

                                  Zacks Equity Research

                                  Merck's Cancer Drug Keytruda Positive in Clinical Studies

                                  by Zacks Equity Research

                                  Merck & Co., Inc. (MRK) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).

                                    Zacks Equity Research

                                    Novartis Presents Data on Tafinlar-Mekinist Combination

                                    by Zacks Equity Research

                                    Novartis AG (NVS) announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

                                      Zacks Equity Research

                                      Gilead Single Tablet Regiment for HIV Good in Phase III

                                      by Zacks Equity Research

                                      Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.

                                        Zacks Equity Research

                                        Pfizer's Trumenba Vaccine Approved by European Commission

                                        by Zacks Equity Research

                                        Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).

                                          Zacks Equity Research

                                          Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers

                                          by Zacks Equity Research

                                          Merck & Co., Inc. (MRK) announced that Keytruda, has received accelerated approval for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors .

                                            Zacks Equity Research

                                            Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion

                                            by Zacks Equity Research

                                            Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.

                                              Zacks Equity Research

                                              Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications

                                              by Zacks Equity Research

                                              Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.

                                                Zacks Equity Research

                                                Ionis (IONS) Stock Falls Despite Positive Inotersen Data

                                                by Zacks Equity Research

                                                Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.

                                                  Zacks Equity Research

                                                  Mylan (MYL) Beats on Q1 Earnings, Revenues Miss Estimates

                                                  by Zacks Equity Research

                                                  Mylan's (MYL) first-quarter results beat on earnings but missed the top line due to a decline in EpiPen sales.